Pfizer Drug Supply Deal Draws Antitrust Scrutiny

Law360, New York (February 16, 2007, 12:00 AM EST) -- Regulators in the United Kingdom are reportedly nearing a decision on whether a controversial deal between Pfizer Inc. and UniChem that would force pharmacists to purchase medicines directly from the American pharmaceutical giant would harm competition in the drug industry.

The United Kingdom’s Office of Fair Trading, which has been evaluating the impact of the proposed changes on competition in the pharmaceutical sector since the end of last year, may announce its decision on the deal in a report on the U.K. Pharmaceutical Pricing Regulation Scheme...
To view the full article, register now.